Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.

Autor: Martin P; Weill Cornell Medicine, New York, NY, USA., Chen Z; Weill Cornell Medicine, New York, NY, USA., Cheson BD; Georgetown University Hospital, Washington, DC, USA., Robinson KS; Dalhousie University, Halifax, NS, Canada., Williams M; University of Virginia Health System, Charlottesville, VA, USA., Rajguru SA; University of Wisconsin Hospital, Madison, WI, USA., Friedberg JW; University of Rochester, Rochester, NY, USA., van der Jagt RH; Ottawa Hospital, Ottawa, ON, Canada., LaCasce AS; Dana-Farber Cancer Institute, Boston, MA, USA., Joyce R; Beth Israel Deconess Medical Center, Boston, MA, USA., Ganjoo KN; Stanford University, San Francisco, CA, USA., Bartlett NL; Washington University School of Medicine, St. Louis, MO, USA., Lemieux B; Centre Hospitalier de l'Universite de Montreal, Montreal, QC, Canada., VanderWalde A; West Cancer Center, Memphis, TN, USA., Herst J; Health Sciences North, Sudbury, ON, Canada., Szer J; Royal Melbourne Hospital, Melbourne, Vic., Australia., Bar MH; Bennet Cancer Center, Stamford, CT, USA., Cabanillas F; Auxillio Cancer Center, San Juan, Puerto Rico., Dodds AJ; St. Vincent's Hospital, Sydney, NSW, Australia., Montgomery PG; St. Luke's Mountain States Tumor Institute, Boise, ID, USA., Pressnail B; Royal Victoria Hospital, Barrie, ON, Canada., Ellis T; Weill Cornell Medicine, New York, NY, USA., Smith MR; Cleveland Clinic, Cleveland, OH, USA., Leonard JP; Weill Cornell Medicine, New York, NY, USA.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2017 Jul; Vol. 178 (2), pp. 250-256. Date of Electronic Publication: 2017 Apr 17.
DOI: 10.1111/bjh.14667
Abstrakt: Despite the long history of bendamustine as treatment for indolent non-Hodgkin lymphoma, long-term efficacy and toxicity data are minimal. We reviewed long-term data from three clinical trials to characterize the toxicity and efficacy of patients receiving bendamustine. Data were available for 149 subjects at 21 sites. The median age was 60 years at the start of bendamustine (range 39-84), and patients had received a median of 3 prior therapies. The histologies included grades 1-2 follicular lymphoma (FL; n = 73), grade 3 FL (n = 23), small lymphocytic lymphoma (n = 20), marginal zone lymphoma (n = 15), mantle cell lymphoma (n = 9), transformed lymphomas (n = 5), lymphoplasmacytic lymphoma (n = 2) and not reported (n = 2). The median event-free survival was 14·1 months. Nine of 12 attempted stem cell collections were successful. With a median follow-up of 8·9 years, 23 patients developed 25 cancers, including 8 patients with myelodysplastic syndrome/acute myeloid leukaemia. These data provide important information regarding the long-term toxicity of bendamustine in previously treated patients. A small but meaningful number of patients achieved durable remissions following bendamustine. These rigorously collected, patient-level, long-term follow-up data provide reassurance that bendamustine or bendamustine plus rituximab is associated with efficacy and safety for patients with relapsed or refractory indolent non-Hodgkin lymphoma.
(© 2017 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: